Incidence of HIV among injection drug users entering drug treatment programs in four US cities
- 38 Downloads
We estimated seroincidence of human immunodeficiency virus (HIV) and prevalence of risk behaviors among injection drug users (IDUs) who accepted voluntary HIV testing on entry to drug treatment. Record-based incidence studies were conducted in 12 drug treatment programs in New York City (n = 890); Newark, New Jersey (n = 521); Seattle, Washington (n = 1,256); and Los Angeles, California (n = 733). Records of confidential HIV tests were abstracted for information on demographics, drug use, and HIV test results. More detailed data on risk behaviors were obtained by a standardized questionnaire. Although overall incidence rates were relatively low in this population (<1/100 person-years), there was a high prevalence of risk behaviors. Needle sharing was reported by more than one-third of the participants in each of the cities. HIV seroincidence rates were up to three-fold higher among younger ID Us. We found that HIV continued to be transmitted among ID Us who had received both drug treatment and HIV counseling and testing. HIV/AIDS (acquired immunodeficiency syndrome) prevention education should continue to be an important component of drug treatment.
KeywordsHIV HIV Risk Behavior Incidence Injection Drug Use Prevalence
Unable to display preview. Download preview PDF.
- 1.Centers for Disease Control and Prevention. AIDS associated with injecting drug use—United States, 1995. MMWR Morb Mortal Wkly Rep. 1996;45:392–398.Google Scholar
- 9.Centers for Disease Control and Prevention. Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR Morb Mortal Wkly Rep. 1989;38(S-7):1–7.Google Scholar
- 10.Substance Abuse and Mental Health Services Administration. Preliminary results from the 1996 National Household Survey on Drug Abuse Rockville, MD: Substance Abuse and Mental Health Services Administration; 1997:25.Google Scholar
- 11.Friedman SR, Jose B, Deren S, Des Jarlais DC, Neaigus A. Risk factors for human immunodeficiency virus seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. Am J Epidemiol. 1996;142:864–874.Google Scholar
- 21.Levine OS, Vlahov D, Brookmeyer R, Cohn S, Nelson KE. Differences in the incidence of hepatitis B and human immunodeficiency syndrome among injecting drug users. J Infec Dis. 1996;173:579–583.Google Scholar
- 22.Monterrosso E, Holmberg S, Robertson P. East versus West Coast differences in risks for and incidence of HIV among injection drug users (IDUs) in the Collaborative IDU Studies (CIDUS). In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22–26, 1997; Washington, DC. Abstract 377.Google Scholar
- 27.Rhodes F, Malotte CK. HIV risk interventions for active drug users: experience and prospects. In: Oskamp S, eds. Understanding and Preventing HIV Risk Behaviors: Safer Sex and Drug Use. Thousand Oaks, CA: Sage Publications, Inc.; 1996:211–214.Google Scholar